Defunct Company
Total Trials
11
As Lead Sponsor
9
As Collaborator
2
Total Enrollment
304
NCT02285088
A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 31, 2014
Completion: May 31, 2017
NCT02497924
A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects
Start: Jun 30, 2015
Completion: Jul 31, 2016
NCT02567682
Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects
Start: Sep 30, 2015
Completion: May 31, 2016
NCT02567695
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
Completion: Jun 30, 2016
NCT02846324
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
Phase: Phase 2
Start: Jun 30, 2016
Completion: Nov 30, 2017
NCT03041909
An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001
Start: Aug 31, 2016
Completion: Aug 31, 2017
NCT02989168
Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest
Start: Nov 30, 2016
Completion: Oct 23, 2017
NCT03161015
Single-Dose PK Study of GBT440 in Subjects With Renal Impairment
Completion: Jul 6, 2017
NCT03051711
Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Conditions
Start: Dec 31, 2016
Completion: Feb 21, 2018
NCT04581356
Voxelotor Sickle Cell Exercise Study
Phase: Phase 4
Role: Collaborator
Start: Sep 21, 2020
Completion: Dec 29, 2021
NCT04335721
A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
Phase: Phase 1/2
Start: Mar 16, 2021
Completion: Oct 7, 2024